AVSOLA Drug Profile

Summary for Tradename: AVSOLA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for AVSOLA

Recent Clinical Trials for AVSOLA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Children's Hospital Medical Center, Cincinnati	Phase 2/Phase 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2/Phase 3
Massachusetts Institute of Technology	Phase 2

See all AVSOLA clinical trials

Pharmacology for AVSOLA

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AVSOLA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AVSOLA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for AVSOLA Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for AVSOLA

Last updated: April 10, 2026

What is AVSOLA?

AVSOLA is the biosimilar version of Amgen’s osteoporosis biologic drug, Prolia (denosumab). It is developed by Fresenius Kabi, targeting the osteoporosis market, which is projected to grow due to increasing aging populations worldwide. As a biosimilar, AVSOLA aims to provide a lower-cost alternative, potentially capturing market share from the reference biologic.

What is the Current Market Position of AVSOLA?

AVSOLA received FDA approval in June 2022. It aims to penetrate the osteoporosis treatment segment, which generated approximately $4.9 billion globally in 2022, with Prolia accounting for a significant share[1].

Key competitors:

• Prolia (Amgen): 55%-60% market share in osteoporosis biologics.
• XGEVA (Amgen): Similar biologic used for cancer-related bone loss.
• Other biosimilars: Incline to enter the market, such as those from Teva and Sandoz, with expected launches within 1-2 years.

Regulatory and reimbursement environment:

• US: FDA-approved biosimilars face challenges related to patent closures and payer acceptance.
• Europe: Biosimilars benefit from earlier acceptance and cost-saving policies, setting a precedent for uptake.

What are the Drivers and Barriers for AVSOLA Market Penetration?

Market Drivers:

• Pricing pressure: Biosimilars typically enter at a 15-30% discount relative to the reference drug. AVSOLA could be priced at 20-25% below Prolia.
• Cost savings mandates: Payers seek less expensive options to control escalations in osteoporosis treatment costs.
• Physician acceptance: Increasing familiarity with biosimilars and positive clinician experience facilitate switching.

Market Barriers:

• Brand loyalty: Established prescriber habits favor branded Prolia.
• Patent rights and legal disputes: Ongoing patent litigation can delay full market access.
• Physician and patient hesitancy: Concerns about biosimilar efficacy and safety persist despite regulatory approval.

What is the Financial Trajectory Expected for AVSOLA?

Revenue projections:

• Initial launch (2022-2023): Limited market share, estimated at 2-5% of the osteoporosis biologics market, generating $10-25 million annually.
• Mid-term (2024-2026): Growing market acceptance with a potential share of 10-15%, boosting revenue to $50-150 million annually.
• Long-term (2027+): Market saturation, projected at 20%, yielding revenues around $200 million or higher, assuming successful expansion and payer acceptance.

Growth factors:

• Payer push for biosimilar utilization.
• Growing osteoporosis prevalence in aging populations.
• Increased physician awareness and comfort endorsing biosimilars.

Key financial metrics:

Year	Estimated Market Share	Approximate Revenue	Notes
2022	2-3%	$10-15 million	Launch phase
2023	4-5%	$20-25 million	Early adoption
2024	8-10%	$40-50 million	Expanded market share
2025	12-15%	$60-75 million	Growth stabilizes
2026	15-20%	$75-100 million	Approaching saturation

Risks and uncertainties:

• Patent litigations delaying market penetration.
• Competitive biosimilar entries.
• Changes in reimbursement policies.

What are the Implications for Stakeholders?

Investors gain insight into the potential revenue streams from AVSOLA, which depends on regulatory developments, market acceptance, and competitive dynamics. Pharmaceutical companies developing biosimilars face competitive pressures but also benefit from mounting demand for cost-effective biologics amid aging demographics.

Key Takeaways

• AVSOLA entered the US market in mid-2022 as a biosimilar for Prolia, targeting a multibillion-dollar segment.
• Market penetration will be gradual, constrained initially by brand loyalty and patent issues.
• Long-term revenue could approach $200 million annually, contingent on payer acceptance, prescriber confidence, and competitive landscape.

FAQs

1. How does AVSOLA compare in price to Prolia?
AVSOLA is expected to be priced at approximately 20-25% below Prolia, aligning with typical biosimilar discount ranges.

2. What patent issues could delay AVSOLA's market share growth?
Patent litigations around the biologic’s formulation and manufacturing process can extend exclusivity periods for Prolia, delaying biosimilar entry.

3. What factors impact AVSOLA’s market growth?
Pricing strategies, payer reimbursement policies, physician and patient acceptance, and the competitive biosimilar landscape influence growth.

4. How will biosimilar adoption affect the osteoporosis treatment market?
Increased biosimilar presence is likely to reduce drug costs, expand access, and pressure branded biologics to adjust pricing.

5. What is the outlook for biosimilar proliferation in the US?
Proliferation is expected to accelerate as patent protections expire and payers push for cost savings, possibly leading to an 8-10% annual growth rate in biosimilar osteoporosis biologics over the next five years.

---

References

[1] EvaluatePharma. (2022). Global Biosimilar Market Report.